Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Gastrointestinal Stromal Tumors 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Neoplasms 3 Leukemia 2 Hematologic Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumor Cancer 1 Rare Tumor 1 Rare Malignant Neoplasm 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Melanoma 1 Lymphangioleiomyomatosis 1 Leukemia, Myeloid, Chronic-Phase 1 Congenital Bone Marrow Failure Syndromes 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡